To determine whether the use of the radial artery (RA) vs the saphenous vein (SV) as the second grafting conduit with the internal thoracic artery (ITA) confers a late-survival advantage in diabetes mellitus (DM).
INTRODUCTION
Event-free long-term survival is the objective of therapy for atherosclerotic coronary artery disease. Long-term outcomes following surgical coronary revascularization are challenging to predict due to the complex and incompletely understood interplay between modifiable elements of surgical strategy insuring optimal graft durability and non-modifiable patient-specific characteristics such as diabetes mellitus (DM) [1] [2] [3] [4] [5] . Indeed, only 52% of long-term mortality can be attributed to a cardiac cause [3] . Although arguably addressable through prudent dietary habits and pharmacological intervention, DM, a known cardiovascular risk factor, has become a worldwide epidemic and not surprisingly, its incidence has risen to 43% in patients undergoing coronary artery bypass grafting (CABG) in the USA in 2011 as evidenced by the Society of Thoracic Surgeons' (STS) Adult Cardiac Surgery Database (www.sts.org/documents). Thus, the issue of optimal surgical strategy, particularly in light of superior surgical outcomes compared with percutaneous approaches [6] , becomes of paramount importance given the, at best, mediocre outcomes reported in most, but not all, studies of surgical revascularization in diabetics. Multiple hypotheses have been advanced to account for the diminished survival in surgically revascularized diabetics, including both cardiac and non-cardiac factors, but their specific roles and pathophysiological mechanisms remain speculative [7, 8] .
Despite the convincing and growing evidence that multiple arterial grafting, in the form of bilateral internal thoracic arteries (BITAs), compared with single internal thoracic arteries (SITAs), improves long-term survival in the general CABG population [2, 3] , the benefits of multiple arterial grafting are less certain among patients with diabetes [9] [10] [11] . We have previously reported [12] that the addition of RA grafts as a second arterial graft to the left internal thoracic artery (LITA)-based CABG showed no meaningful impact on intermediate-term survival in both insulin and non-insulin-dependent DM. Given that arterial grafting survival benefits may require up to a decade to become apparent [2, 3] and relying on an evolving increasingly sophisticated methodology to minimize the confounding effects of nonrandom patient selection, we review the long-term outcomes of our experience with multiple arterial grafting, in the form of a single ITA complemented with radial artery (RA) grafting plus or minus additional saphenous vein (SV) grafts (ITA/RA), as opposed to single ITA with only supplementary vein grafting (ITA/SV) in diabetic patients. We also aimed to objectively investigate whether the ITA/RA vs ITA/SV late survival varies for specific factors such as for gender, type of diabetes, coronary disease severity, preoperative renal failure and finally, left ventricular (LV) dysfunction.
MATERIALS AND METHODS
This investigation is a retrospective analysis of a prospectively collected cardiac surgery database approved by the Institutional Review Board at Mercy Saint Vincent Medical Center (MSVMC, Toledo, OH, USA). The database is collected and reported in accordance with the STS Adult Cardiac National Database definitions and criteria. Additional review of hospital records or interviews of patients was not needed, and informed consent requirement was waived.
Patients and coronary grafting
The DM study population was derived from patients undergoing CABG surgery at MSVMC between January 1994 and March 2007. Patients were excluded in case they were non-diabetics, were salvage patients, early or operative death [in-hospital death (any time) or out-of-hospital death within 30 days of surgery], had CABG combined with concomitant acquired or congenital cardiac (valve) or aortic surgery and received bilateral ITA, RA grafts only, SV grafts only, ITA grafts only, RA and SV grafts and no ITA. Patients were also excluded in the case of unavailable or erroneous Social Security number to allow a verifiable Social Security Death Index search. Alternatively, patients were included in the study if they were diabetics, underwent CABG and had two or more completed coronary grafts that included a single ITA with additional SV, RA or both SV and RA. Diabetics were defined as those treated with either oral hypoglycaemic agents, insulin or both. Primary comparison criteria were based on whether RA was used as a second arterial conduit (ITA/RA) or not (ITA/SV).
The surgical approach was previously described [5, 12] . Cardiopulmonary bypass was used in a large majority of patients (>95%). Aorto-coronary grafting was the method of choice (>95%) unless aorta quality was suboptimal or for graft length. Over the study period, SV and RA graft harvesting progressed from an open to an endovascular approach. Initially used calcium channel antagonists in RA patients were abandoned as data showing no impact became available. The grafting strategy always aimed to maximize arterial grafts (either via sequential construction or via the use of bilateral RA grafts) and to allocate arterial grafts to the largest and most important target vessels either based on the degree of stenosis or the largest supplied myocardial territory. Initially, RA was placed in both the right and left coronary systems, but with the emergence of data suggesting a suboptimal RA graft durability in the right coronary system, more emphasis was placed on targeting the left system. Concurrently, RA grafting was more exclusively used in targets with a higher degree of stenosis (>75%), however, relatively large RA grafts were also placed in smaller target vessels with only moderate degree of stenosis (>50%).
Follow-up
Long-term all-cause mortality data were obtained from our service patient follow-up and verified from individual patient queries of the US 'Social Security Death Index' database in February 2012 (http://ssdi.genealogy.rootsweb.com). Database records were updated for missing death information when necessary. The follow-up period had a minimum of 56 (March 2007 patients) and a maximum of 217 ( January 1994 patients) months of follow-up. The last recorded death in the analysed patient series occurred in February 2012.
Propensity-score model and matching
ITA/RA and ITA/SV cohorts exhibited significant differences in their demographic, risk factor and operative variables (Table 1) . Because such differences can influence outcome comparisons in observational treatment groups, we used propensity-score matching to derive demographics, risk factor and operation-matched cohorts of equal size, in which the use of RA was considered treatment. The propensity score, or equivalently the probability that a given patient receives an RA graft, was derived via a nonparsimonious binary logistic regression model that included patient factors given in Table 1 , irrespective of their significance, with avoidance of highly collinear variables. Coronary disease and number of grafts were incorporated into the model via a completeness of revascularization index (CRI = #Grafts − # of diseased vessels) derived from the difference between the number of grafts (#Grafts) and vessel disease (VD = 1, 2 or 3) such that: CRI = −1 (incomplete), 0 (complete), 1 (complete+) and ≥2 (complete++). Blood transfusion was also added into the propensity model given the increased evidence that it independently predicts late mortality [13] . Five categorical patient factors were excluded from the propensity model: insulin-dependence, gender, three-vessel disease, preoperative renal failure and preoperative LV dysfunction (defined as ejection fraction ≤40%). These factors were excluded from the propensity model because of an a priori decision to (i) consider related ITA/RA vs ITA/SV comparisons in their respective sub-cohorts and, hence, (ii) always strictly match these factors in all propensity-matched pairs to insure that we have an identical ITA/RA and ITA/SV patients who are always perfectly matched and well matched for all other remaining factors via propensity-score matching ( Table 2 ). The resulting model propensity scores were distinctly different for RA cohorts (mean ± standard deviation (SD): 0.495 ± 0.175 vs 0.349 ± 0.171, respectively; P < 0.001) when compared with the SV cohort. The C-statistic value [area under the receiver operating curve (ROC) curve] of the propensity model was 0.72 ± 0.011, indicating moderately good discrimination. Bold values signify factors which were strictly matched (in our restricted matching approach) rather than the usual propensity-matched approach. Therefore, there were identical counts (N), frequencies (%) and zero % differences for these factors after matching. IABP: intra aortic balloon pump; r: restricted category during matching (perfectly matched); t: unpaired t-test; c: chi-square test; P: paired t-test; M: McNemar test.
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A computer algorithm was used to obtain highly restricted, greedy (1-to-1 or no sharing) ITA/RA and ITA/SV propensity-score-matched pairs. This highly restrictive form of propensity matching for the five prespecified factors is fairly novel, and is motivated by the fact that late survival following CABG is significantly and substantially influenced by these five factors, and because we aimed to separately explore the potential RA survival benefit in their corresponding sub-cohort (e.g. insulin: yes vs no) of the diabetic population. The developed strict matching approach insured that, irrespective of the considered sub-cohort comparison, all these five factors are always perfectly matched in addition to matching of the propensity scores to reduce potential residual confounding due to all remaining patient factors. ITA/RA patients were always matched to the closest available ITA/SV propensity-score counterpart to within ±2.5% difference. The adequacy of patient group matching was achieved by testing the standardized difference, d(%), separately for each factor and based on whether they were continuous, d cont , or categorical, d categ , data types as follows:
where x and s are the mean and SDs of the ITA/RA (R) and ITA/ SV (V) patients, and
where p R and p V are the prevalences of the dichotomous variables. Adequate matching was based on d cont and d categ ≤10% [14] .
Statistical methods
Continuous and categorical data were expressed as mean ± SD or percentages, respectively. As appropriate, for prematching univariate comparisons, χ 2 or Fisher's exact tests were used for categorical variables, while unpaired t-test or the non-parametric Mann-Whitney rank sum test was used for continuous variables. After propensity matching, the McNemar test (categorical factors) and paired t-test (continuous factors) were used. Unadjusted survival comparisons for the baseline and propensity-matched cohorts were done via Kaplan-Meier analysis with statistical significance based on the log rank (Mantel-Cox) tests. In the matched cohorts, survival risk ratios (95% confidence interval) for investigating the effect of ITA/RA grafting method (vs ITA/SV) were derived by Cox regression analysis excluding early mortality (in-hospital or within 30 days of CABG). A two-tailed P-value <0.05 was always used to indicate significance. Statistical analysis and model fitting were done using the SPSS version 19.0 software (IBM, Armonk, NY, USA).
RESULTS
All patients
The study diabetic population following exclusions consisted of 1348 ITA/SV and 933 ITA/RA patients. Patient factors were substantially different between the unmatched ITA/RA and ITA/SV sub-cohorts (Table 1) . ITA/SV patients were older, more insulindependent, had more co-morbidities and were more likely to receive blood transfusion. ITA/RA patients were more obese and more likely to be males, and had more multiple vessel disease and higher revascularization index (Table 1) .
Unadjusted 16-year survival was significantly better for ITA/RA when compared with ITA/SV sub-cohorts [HR = 0.64 (0.64-0.74); 
Propensity-matched patients
The described five-factor matching restriction in addition to propensity matching resulted in 578 matched ITA/RA and ITA/SV pairs (62% of ITA/RA patients). All patient factors were comparable with all differences <10% (Table 1) . Propensity scores of restricted sub-cohorts were also similar after matching (Table 2) Table 4 ). Considering gender, coronary vessel disease and LV dysfunction-matched sub-cohorts ( Fig. 3 and Table 4 Table 4 ). These results in the overall matched groups and the various sub-cohorts remained essentially unchanged when the propensity score was used for further risk adjustment (refer to propensity adjusted HR in Table 4 , and the related Supplementary Table 1 for the hazard ratios of the propensity scores).
DISCUSSION
The results of this study, which both increases the number of patients extends the follow up period of our previous report (12) , supports RA use in diabetics to extend long term survival. Sub-cohort analysis revealed a statistically significant survival advantage with RA use in males, patients with preserved LV function, three-vessel coronary artery disease (CAD) and patients with non insulin dependent diabetes mellitus (NIDDM). Significantly, there was no difference in long-term survival in patients with insulin dependent diabetes mellitus (IDDM), patients with left ventricular ejection fraction (LVEF) of <40% or in those with less than three-vessel CAD. These results constitute, Analysis was done on all patients using the backward elimination method and confirmed by the forward selection method.
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to our knowledge, the first report documenting significantly enhanced survival associated with RA utilization in diabetics. Given the growing diabetes epidemic and the suboptimal survival of diabetic patients with CAD documented by most surgical studies [1, 11, 12, 15] , an innovative therapeutic approach is needed. There are a small number of reports of favourable outcomes with the use of BITA grafts in the diabetic CABG population, however, most investigators were unable to convincingly demonstrate a comparably improved survival with that seen in the overall CABG population with BITA use. Consistent with our observations, Lev-Ran et al. [16] showed improved 7-year survival, decreased major adverse cardiac events and decreased cardiac-specific mortality with multiple arterial grafts in the form of left coronary artery system BITA grafting compared with traditional LITA saphenous vein graft (SVG) configuration in a small series of patients with NIDDM undergoing CABG. Endo et al. [11] reported improved survival with BITA use in only those diabetic patients with an ejection factor over 40%, a finding that is similar to our experience with RA grafting. In contradistinction, neither Hirotani et al. [9] nor Toumpoulis et al. [10] were able to document any effect on long-term survival in diabetic CABG patients with BITA compared with SITA. Tranbaugh et al. [4] , in a study evaluating the potential benefits of RA grafting in the general CABG population, found that RA utilization improved survival, while in the diabetic (any type) sub-cohort of their series, the improvement did not reach statistical significance (P = 0.052). Locker et al. [17] , in an analysis of a large contemporaneous low-risk CABG population, identified improved survival with multiple arterial grafting, principally BITA, in diabetics in general, but with no subgroup analysis. The divergent conclusions of these studies may be due to the differing methodologies utilized to minimize the confounding effects of the non-random patient selection to undergo either a single or multiple arterial revascularization strategy as well as the small number of subjects in most of these studies.
We have previously reported our experience with multiple arterial grafting in the diabetic CABG population [12] . We compared intermediate-term survival (mean follow-up of 5.7 years) between the propensity-matched (based on 47 specific demographic and operative factors) ITA/RA (±SVG) group vs the ITA/ SVG group. In contradistinction to our current results, we were unable to document intermediate-term survival differences between the two grafting strategies. Sub-cohort analysis found no difference in survival either in NIDDM or in IDDM patients. This lack of appreciable difference in survival with RA grafting stands in contrast to the results of the current study. The discrepancies are likely due to several significant differences between the two studies. First, the current report has increased the number of subjects from 1516 to 2281. Secondly, the follow-up period was increased from 10 to 16 years. Thirdly, the utilization of RA has progressively transitioned over time from a highly selective use in the early phases of our experience to a consistently routine use currently, paralleling our comfort level with this conduit. Thus, in the later phases of the current study, the RA was used more liberally across a wider spectrum of the diabetic population, more closely reflecting our current practice patterns. Fourthly, only long-term mortality data were used in the current analysis in contradistinction to the reliance on both acute and intermediate-term mortalities of our previous analysis. Fifthly, and most importantly, the current propensity model included the completeness of the revascularization index and the use of blood transfusion given that they are now recognized determinants of long-term survival after CABG [13, 18] . These elements were not included in the propensity matching in our previous analysis nor most other studies focusing on CABG survival in general or within the diabetic subcohort. Additionally, to insure a more robust and accurate matching between the ITA/RA and ITA/SV groups in the current study, we developed a five-factor (insulin use, gender, three-vessel disease, preoperative renal failure and LV dysfunction) restrictive propensity-matching algorithm such that these factors were purposely excluded from propensity-score calculation. They were chosen a priori based on their documented importance in the long-term survival of CABG patients [1] as well as our interest in the impact of RA grafting within these specific diabetic sub-cohorts. With this approach, for any propensity-matched pair, the value of these factors was always perfectly matched. Such a highly restrictive process should enhance the fidelity of the matching of patients, but will also necessarily reduce the final number of matched pairs available for analysis. In contrast, our previous analysis only restricted diabetes type and did so by separate derived propensity models for insulin and non-insulin patients. This meant that the derived propensity scores were based on an increasingly limited number of patients.
Within this framework, our findings indicate that adding an RA graft to the traditional ITA/SVG configuration is beneficial in the entire diabetic study group undergoing CABG, offering a statistically significant incremental improved long-term survival up to 16 years postoperatively (P = 0.012). This effect was exclusively driven by survival enhancement in the NIDDM cohort (P = 0.007) with no appreciable improvement in survival in the IDDM cohort (P = 0.61), although the number of comparison pairs in this cohort was limited (169 pairs). We speculate that the documented improved long-term survival in the overall study group is due to the same improved durability of RA grafts vs SVG in the diabetic patient population that has been documented in the overall CABG population [4, 5, 19] . Although there is limited comparative arterial patency data available in diabetic vs non-diabetic patients, our hypothesis is supported by data from the Radial Artery Patency Study (RAPS) study [20] , in which the RA graft patency superiority over SVG at 1 year in the nondiabetic population was even further exaggerated in their diabetic population. Indirect evidence supporting an overall improved arterial graft patency hypothesis in diabetics comes from the Bypass Angioplasty Revascularization Investigation (BARI) study, which reported that long-term survival was enhanced only in diabetics grafted with LITA and SVG compared with exclusively SVG. The comparable resistance of RA and ITA grafts to atherosclerosis as evidenced by the trivial long-term (up to 20 years) attrition of RA grafts [21] and the observation that atherosclerosis is not implicated in the failure of RA grafts [22] add further circumstantial evidence to our contention.
Sub-cohort analysis revealed specific patient demographics in which RA utilization improved long-term survival. Importantly, we were unable to identify any group of patients in whom RA use was detrimental to long-term survival. The lack of effect of RA use on survival in the IDDM cohort may be due to the fact that patients with IDDM have a significantly worse mortality than their NIDDM counterparts [12, 23] , potentially negating any positive graft-driven survival advantage. Thus, it is possible that IDDM patients more likely die of non-cardiac causes with their arterial grafts intact, rather than of cardiac causes attributable to the failure of their arterial grafts. Although the BARI study [6] does not differentiate between IDDM and NIDDM, its finding of comparable cardiac-specific mortality rates in diabetics and nondiabetics, but a significantly higher non-cardiac mortality rate of 13.4% in diabetics vs 4.7% in non-diabetics, suggests a limit on the effect of enhanced arterial graft durability on survival in diabetics. We are unable to comment on this hypothesis as the specific cause of death is unavailable in our data set.
Given the known negative impact of ventricular dysfunction on survival, premature death may also account for the lack of effect on survival in the ITA/RA patients with diminished LVEF of <40%, vs the enhanced survival noted in diabetics with an LVEF >40%. Similar findings were reported by Endo et al. [11] , in the case of diabetics grafted with BITA. Notably, there was no increased risk in these high-risk patients with poor LV function with RA use. 
Sub-cohort analysis revealed a highly statistically significant improved survival with RA grafting in male patients (P < 0.001), but no appreciable impact of RA utilization on the long-term survival of female diabetic patients (P = 0.55). The sex-specific difference in survival among diabetics may be simply an epiphenomenon due to the fact that the female cohort was characterized by a significantly greater prevalence of insulindependence (40.4 vs 23.2%; P = 0.000) and non-triple coronary vessel disease (31.9 vs 23.6%; P = 0.036) compared with men. Both of these demographics (non-triple vessel and IDDM) were associated with essentially identical late CABG survival for the two revascularization approaches (ITA/RA or ITA/SV) and thus may overwhelm any gender-specific differences in survival. In fact, this may also explain our recent finding that while RA use as a second arterial conduit was associated with a significant late-survival benefit in females overall (HR = 0.75; P = 0.045), this Comparison of Kaplan-Meier survival in restricted, propensity-matched ITA/SV vs ITA/RA CABG diabetic patient sub-cohorts based on: gender (male/ female-top), three-vessel disease (yes/no-middle) and LV dysfunction (yes/no-bottom). All statistical comparisons were made using the log rank (Mantel-Cox) test.
RA effect was relatively less than that seen in male counterparts (HR = 0.65; P < 0.001) [24] . Given that only very limited gender specific graft durability data exist in the literature and are unavailable for this study population, a definitive explanation for our gender associated outcomes is difficult. It is possible that diabetes has a more profoundly negative prognosis in females than in males, a contention that is supported by the finding of the Framingham Heart Study [25] , in which the incidence of coronary heart disease is equivalent between male and female diabetics, suggesting that the female protective effect is lost in the diabetic milieu. Others have also reported that the female sex and diabetes are both independent predictors of graft failure [15, 20] , but the cumulative effects of both factors combined are unknown. Interestingly, Desai et al. [19] reported an equivalent RA patency in males and females in a general CABG population, but a significantly worse SVG patency in females than in males, suggesting a preferential benefit of RA in females. Whether a similar pattern is true in diabetics is unknown.
We also identified a survival advantage with RA grafting in patients with triple-vessel CAD, which was not apparent in patients with a lesser degree of coronary atherosclerosis. This finding may reflect that, in diabetics with a lesser degree of CAD, a single arterial graft in the form of the ITA is enough to optimize survival with an additional arterial graft offering little incremental survival advantage. However, with progressively increasing atherosclerotic burden manifest by the presence of triple-vessel CAD, the benefits of a second arterial graft become apparent and realizable. We reported a similar improved longterm survival only in patients with triple-vessel CAD in the general CABG population who underwent an all-arterial revascularization compared with the standard ITA/SVG platform [18] .
Predictors of long-term mortality in diabetics (Table 3) for the most part corroborate the well-defined risk factors related to long-term outcomes identified in other studies [1] including IDDM, renal failure, peripheral vascular disease, cerebrovascular disease, chronic obstructive pulmonary disease (COPD), congestive heart failure and ejection fraction. We also defined several factors that are less well associated, but also previously reported, with long-term survival: blood transfusion [13] , RA use [4] and revascularization index [18] . Paradoxically, we also identified hypercholesterolaemia as a correlate of long-term survival. Plausibly, this may perhaps be due to a hyperlipidaemia diagnosis-driven more-aggressive anti-lipid pharmacological treatment in these individual as opposed to a pharmacologically less-intense anti-lipid therapy in those patients without this diagnosis. As the specific lipid profiles are unavailable to us, this reasoning remains speculative.
The limits of our study include its retrospective nature, exposing the results to possible confounding patient selection bias. Because of its single-practice setting, the conclusions drawn may have limited generalizability to the cardiac surgical community at large. Preoperative hemoglobin A1c (HbA1C) levels are unavailable for analysis, and the degree of perioperative and long-term glycaemic control is unknown. In addition, we do not have graft patency data or the cause of death to adjudicate between a cardiac and a non-cardiac aetiology which, in turn, could indicate whether there is a possible role for graft durability as the mechanism for the enhanced survival in patients grafted with the RA. Finally, we did not include the effects of subsequent cardiac interventions within the study cohort on survival, be they percutaneous or surgical.
In conclusion, the present analysis adds to the growing body of literature documenting the versatility and efficacy of RA grafting in contemporary CABG surgery. This study utilizes restricted propensity-matching methodology, and documented improved long-term survival in diabetic patients who receive ITA/RA grafts compared with the traditional ITA/SVG configuration. Given the lack of an increased risk of sternal wound complications associated with bilateral ITA use, the documented sub-cohortspecific survival benefit and, importantly, the lack of an identifiable group adversely effected by RA use, we enthusiastically support the use of RA in diabetics.
